# OKAIN: A comprehensive oncology knowledge base for the interpretation of clinically actionable alterations

## TL;DR

OKAIN is a precision oncology tool that helps identify clinically actionable genetic mutations in cancer patients.

## Contribution

OKAIN introduces a weighted evidence analysis system for assessing actionable cancer mutations with over 100,000 variants.

## Key findings

- OKAIN contains over 100,000 variants in 1,239 cancer-associated genes.
- It includes 12,409 therapeutic evidence entries, with 2,600 classified as Level A.
- The database integrates 864 entries from Chinese guidelines or NMPA labels.

## Abstract

The increased use of next-generation sequencing in clinical genetic testing has resulted in the identification of several genetic variations with possible therapeutic implications. We developed OKAIN (https://szcube.origimed.com), an algorithm tool that assesses clinically actionable mutations using a precision oncology knowledge database. OKAIN employs a weighted evidence analysis system to deliver final clinical annotation outcomes for intricate variations. As of now, OKAIN has amassed over 100,000 variants in 1,239 cancer-associated genes, encompassing 12,409 entries of therapeutic evidence in 471 genes. This collection highlights 2,600 Level A evidence entries in 66 genes, with 864 entries derived from the National Medical Products Administration labels or Chinese guidelines. OKAIN acts as a precision oncology knowledge base for the assessment of clinically actionable alterations, integrating exhaustive data related to cancer-associated genomic variants and therapeutic efficacy. Analyzing patient variants with OKAIN reveals more actionable targeted therapy or immunotherapy options, potentially improving treatment outcomes.